Mufg Securities Americas Inc. Invests $135,000 in Solventum Co. (NYSE:SOLV)

Mufg Securities Americas Inc. purchased a new position in Solventum Co. (NYSE:SOLV) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,040 shares of the company’s stock, valued at approximately $135,000.

A number of other large investors also recently modified their holdings of the business. Norges Bank acquired a new stake in shares of Solventum in the 4th quarter worth about $203,740,000. Boston Partners acquired a new stake in shares of Solventum in the 4th quarter worth about $110,378,000. Independent Franchise Partners LLP increased its holdings in shares of Solventum by 105.0% in the 4th quarter. Independent Franchise Partners LLP now owns 1,603,154 shares of the company’s stock worth $105,904,000 after acquiring an additional 821,272 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in shares of Solventum by 41.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,193,361 shares of the company’s stock worth $78,833,000 after acquiring an additional 347,669 shares during the period. Finally, Candlestick Capital Management LP increased its holdings in shares of Solventum by 67.7% in the 4th quarter. Candlestick Capital Management LP now owns 802,606 shares of the company’s stock worth $53,020,000 after acquiring an additional 323,920 shares during the period.

Solventum Stock Performance

Shares of SOLV opened at $74.08 on Friday. Solventum Co. has a one year low of $47.16 and a one year high of $85.92. The company has a 50-day moving average of $69.79 and a two-hundred day moving average of $71.27. The stock has a market cap of $12.82 billion and a price-to-earnings ratio of 34.30. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, May 8th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.19 by $0.15. The company had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.02 billion. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.08 earnings per share. On average, equities research analysts expect that Solventum Co. will post 6.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Piper Sandler dropped their price objective on shares of Solventum from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Friday, May 9th. The Goldman Sachs Group raised their target price on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Morgan Stanley raised their target price on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. Wells Fargo & Company raised their target price on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Finally, Mizuho raised their target price on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, Solventum currently has a consensus rating of “Hold” and a consensus target price of $79.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.